Tag Archive for: CNS disorders

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

/in

A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1 This breakthrough innovation represents a major milestone in Neuraxpharm’s commitment to advancing both digital and personalised solutions that enhance safety and improve quality of life […]

Read more

New ublituximab data in multiple sclerosis to be presented at ECTRIMS Congress 2025 alongside partner TG Therapeutics

/in

Barcelona, Spain and Düsseldorf, Germany – 22 September, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces its participation at 41st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Annual Congress, taking place in Barcelona from 24–26 September. […]

Read more

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

/in

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program Barcelona, Spain – […]

Read more

Novo Holdings participates in $372.5 million Series D financing of MapLight Therapeutics to advance differentiated CNS therapies

/in

Financing to support Phase 2 trials of lead program for schizophrenia and Alzheimer’s disease psychosis, and expansion of CNS pipeline San Francisco, US, 28 July 2025 – Novo Holdings, a leading life science investor, today announced its participation in a $372.5 million Series D financing of MapLight Therapeutics (“MapLight”), a clinical-stage biopharmaceutical company focused on improving […]

Read more

Neuraxpharm expands operations into the Middle East

/in

Brings leading CNS products, including BRIUMVI® (ublituximab), to new territories Dubai, UAE, Barcelona, Spain and Düsseldorf, Germany – 1st October, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of Neuraxpharm Middle East to cover the six members of the Gulf Cooperation […]

Read more